Pharma Focus Asia

FUJIFILM Diosynth Biotechnologies Invests US$2 billion to Construct New Manufacturing Facility in North California, USA

Introduction:

FUJIFILM Diosynth Biotechnologies is investing US$2 billion to open new large-scale cell culture manufacturing facility in North Carolina, USA.

Features:

The upcoming facility will emerge as the Contract Development and Manufacturing Organisation (CDMO), boasting cutting-edge biopharmaceutical manufacturing equipment and technology. 

The facility's scale is emphasized by the inclusion of two expansive manufacturing suites, each equipped with 4 x 20,000 L bioreactors.

This facility has been designed with future scalability in mind, spanning an area of nearly 1,000,000 square feet. Its adaptability allows seamless expansion, accommodating the integration of an additional 24 x 20,000 L bioreactors to cater to upcoming projects.

Once operational, this site will serve as a comprehensive hub offering drug substance manufacturing, automated fill-finish and assembly, as well as packaging and labelling services to the global biopharmaceutical domain.

Moreover, this site is set to be a significant job creator, aiming to generate 725 manufacturing jobs in North Carolina by the end of 2028.

Specifications:

Name    FUJIFILM Diosynth Biotechnologies
Type      New Construction
Budget   US$2 billion
Year       2028

magazine-slider-imageHexagon - Expert Insights WebinarMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference